相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1921
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A nationwide phase III randomized controlled trial of 410 cancer survivors found that a 4-week structured yoga program (YOCAS) significantly reduced overall mood disturbance, anxiety, and fatigue compared to standard care alone. - Participants in the yoga group experienced a 5.08-point reduction in mood disturbance (moderate-to-large effect), a 0.72-point reduction in anxiety (small-to-medium effect), and a 1.49-point reduction in fatigue (medium-to-large effect). - Mediation analyses revealed that improvements in mood disturbance and fatigue each accounted for approximately 25% of the insomnia improvements associated with the yoga intervention. - The findings, presented at the 2026 ASCO Annual Meeting, support structured yoga as a nonpharmacologic option for managing multiple cancer-related side effects simultaneously without adding another drug.
- Indivumed has expanded its collaboration with the University of Rochester Medical Center's Wilmot Cancer Institute to accelerate development of novel cancer therapeutics using patient-centric research approaches. - The partnership will focus on creating patient-derived tumor models from high-quality tissue samples with minimized ischemia time under ten minutes to ensure sample integrity. - Initial research targets advanced stages of solid cancers including colorectal, pancreatic, lung, and breast cancer, with potential expansion to other cancer types. - The collaboration leverages Indivumed's AI-powered data analytics and standardized tissue collection platform to identify and validate novel molecular cancer targets for precision oncology.
- Phase 2b open-label extension study confirms tildrakizumab maintains favorable safety profile over 208 weeks in 281 psoriatic arthritis patients. - Only 6.0% of patients discontinued treatment due to adverse events, with most experiencing mild to moderate side effects like upper respiratory infections. - IL-23 inhibitors show lower serious infection risk compared to other biologics, positioning them as preferred choice for high-risk patients. - Long-term safety data supports potential combination therapy strategies with anti-TNF agents for enhanced psoriatic arthritis treatment.
- The BIO-LIBRA study achieved unprecedented female representation at 48% in cardiac device trials, revealing that males with non-ischemic cardiomyopathy face twice the risk of death or life-threatening arrhythmias compared to females. - One-year results showed 13% of males experienced adverse outcomes versus 6% of females, representing a 52% lower risk for female patients with implantable cardiac defibrillators. - Researchers overcame traditional enrollment barriers by scheduling visits with routine care, using remote monitoring, and removing age or comorbidity exclusions that disproportionately affected female participation. - The study demonstrates that better demographic representation in clinical trials benefits all patients by providing more accurate risk stratification and treatment guidance.
- The subcutaneous formulation of daratumumab with hyaluronidase-fihj (Darzalex Faspro) allows multiple myeloma patients to complete treatment visits in under one hour compared to 3-4 hours with intravenous administration. - After the first treatment cycle, patients receiving subcutaneous daratumumab can forgo premedication and observation requirements that are necessary with each intravenous infusion cycle. - The subcutaneous formulation maintains a similar adverse event profile to intravenous daratumumab while providing improved convenience through a 15 ml injection administered slowly in the abdomen. - Healthcare providers emphasize that the subcutaneous option has become the preferred formulary choice due to reduced chair time and improved patient experience without compromising safety or efficacy.
- Applied Cognition published a groundbreaking study in Nature Biomedical Engineering demonstrating the first continuous, non-invasive measurement of human glymphatic function using novel electrical impedance spectroscopy technology. - The platform enables real-time monitoring of the brain's waste clearance system that removes Alzheimer's-associated proteins like amyloid and tau, overcoming limitations of slow, high-cost MRI scans. - The company has already identified a promising drug candidate that improves glymphatic clearance in early clinical trials and is advancing its lead program for early-stage Alzheimer's disease. - The technology revealed for the first time in humans how EEG and cardiovascular physiology contribute to sleep-active glymphatic activity, opening new avenues for drug discovery.
- A new international study finds that physicians consistently underestimate symptom severity in pulmonary arterial hypertension patients, with particularly notable discrepancies in higher WHO functional classes. - While both patients and physicians identified dyspnea as the most common symptom (57% and 62% respectively), significant disparities emerged in other symptoms, with 55% of patients reporting fatigue compared to only 34% of physicians noting it. - The research, spanning the US, Europe, and Japan, demonstrates that higher WHO functional class correlates with lower quality of life, highlighting the need for improved physician-patient communication.
- Current treatment options for severe RSV in adults remain largely limited to supportive care, emphasizing the crucial importance of preventive vaccination strategies. - Recent studies show RSV hospitalizations result in higher rates of ICU admission and mechanical ventilation compared to COVID-19 and influenza, with double the mortality risk versus flu. - Three FDA-approved RSV vaccines - Arexvy, Abrysvo, and mRESVIA - are now available for adults 60 and older, with expanded approvals for younger at-risk populations.
